Abstract
Gene therapy was originally conceived to treat monogenic diseases. The replacement of a defective gene with a functional gene can theoretically cure the disease. In cancer, multiple genetic defects are present and the molecular profile changes during the course of the disease, making the replacement of all defective genes impossible. To overcome these difficulties, various gene therapy strategies have been adopted, including immune stimulation, transfer of suicide genes, inhibition of driver oncogenes, replacement of tumor-suppressor genes that could mediate apoptosis or anti-angiogenesis, and transfer of genes that enhance conventional treatments such as radiotherapy and chemotherapy. Some of these strategies have been tested successfully in non-small-cell lung cancer patients and the results of laboratory studies and clinical trials are reviewed herein.
Publication types
-
Review
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Apoptosis / genetics
-
Carcinoma, Non-Small-Cell Lung / genetics
-
Carcinoma, Non-Small-Cell Lung / metabolism
-
Carcinoma, Non-Small-Cell Lung / therapy
-
Clinical Trials as Topic
-
Combined Modality Therapy
-
Drug Evaluation, Preclinical
-
Gene Expression Regulation, Neoplastic
-
Genes, Tumor Suppressor
-
Genetic Therapy / methods*
-
Humans
-
Lung Neoplasms / genetics*
-
Lung Neoplasms / metabolism
-
Lung Neoplasms / therapy*
-
Mutation
-
Radiotherapy / methods
-
Tumor Suppressor Protein p53 / genetics
-
Tumor Suppressor Protein p53 / metabolism
-
Tumor Suppressor Proteins / genetics
-
Tumor Suppressor Proteins / metabolism
Substances
-
TUSC2 protein, human
-
Tumor Suppressor Protein p53
-
Tumor Suppressor Proteins